Efficacy of Intravitreal Injection of Aflibercept in Neovascular Age-Related Macular Degeneration With or Without Choroidal Vascular Hyperpermeability
- 13 November 2014
- journal article
- research article
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 55 (12) , 7874-7880
Abstract
Purpose.: To compare therapeutic responses to intravitreal aflibercept and ranibizumab in neovascular age-related macular degeneration (AMD)-affected eyes with and without choroidal vascular hyperpermeability (CVH). Methods.: Medical records of 216 consecutive patients (216 eyes) with treatment-naïve exudative AMD who had received three monthly intravitreal injections of aflibercept (2 mg) and ranibizumab (0.5 mg) at a single institution were analyzed. The associations of CVH with functional and morphologic changes were compared between the treatment groups. Results.: Although foveal thickness (P = 0.85) and visual acuity (P = 0.13) changes were not significantly different between the treatment groups, subfoveal choroidal thickness (CT) (P = 0.001) and pigment epithelial detachment (PED) height (P = 0.043) decreased more profoundly in the aflibercept-treated group. The incidence of dry macula after treatments was lower in the ranibizumab-treated eyes with CVH than in those without CVH (P = 0.043), but it showed no significant difference between the aflibercept-treated eyes with and without CVH (P = 0.74). The aflibercept-treated eyes with CVH showed a higher incidence of dry macula (P = 0.04) and greater decrease in subfoveal CT (P = 0.002) than the ranibizumab-treated eyes with CVH. Conclusions.: Intravitreal aflibercept can achieve remission of exudative retinal changes in eyes with AMD even in the presence of CVH. In addition, it showed greater effects on the choroid and PED than intravitreal ranibizumab. The possible relationship between CVH suppression and decrease in CT warrants further study.Keywords
This publication has 26 references indexed in Scilit:
- Choroidal Thickness Changes After Intravitreal Ranibizumab and Photodynamic Therapy in Recurrent Polypoidal Choroidal VasculopathyAmerican Journal of Ophthalmology, 2013
- Relationship Between Clinical Characteristics of Polypoidal Choroidal Vasculopathy and Choroidal Vascular HyperpermeabilityAmerican Journal of Ophthalmology, 2013
- Choroidal Thickness, Vascular Hyperpermeability, and Complement Factor H in Age-Related Macular Degeneration and Polypoidal Choroidal VasculopathyInvestigative Ophthalmology & Visual Science, 2012
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis, 2012
- VEGF Trap-Eye for the treatment of neovascular age-related macular degenerationExpert Opinion on Investigational Drugs, 2009
- Predicted biological activity of intravitreal VEGF TrapBritish Journal of Ophthalmology, 2008
- Polypoidal Choroidal Vasculopathy with Choroidal Vascular HyperpermeabilityAmerican Journal of Ophthalmology, 2006
- VEGF-Trap: A VEGF blocker with potent antitumor effectsProceedings of the National Academy of Sciences, 2002
- Indocyanine green angiography is of value for the diagnosis of chronic central serous chorioretinopathy in elderly patientsGraefe's Archive for Clinical and Experimental Ophthalmology, 1998
- INDOCYANINE GREEN VIDEOANGIOGRAPHY OF OLDER PATIENTS WITH CENTRAL SEROUS CHORIORETINOPATHYRetina, 1996